Indication
Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month
Loading your page…
Loading your page…
Migraine Disorders
Marketing Authorisation Holder: AbbVie Deutschland GmbH & Co. KG
EMA Authorisation: 11/08/2023
INN: atogepant
AI Drug & Interaction Analysis
Free account required
Ask Osler about Aquipta: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.